BioInvent International to carry out rights issue
BioInvent International AB (publ), a research-based pharmaceutical company focused on developing antibody drugs, is carrying out a rights issue with preferential right for the company’s shareholders.
The Board of Directors´ decision to carry out the rights issue, which will provide the company with approximately SEK 105 million, was approved by an extraordinary general meeting on 9 March 2012.
BioInvent was advised by Mannheimer Swartling on the rights issue. The firm acted as project leader throughout the process and was responsible for the prospectus. Mannheimer Swartling’s team consisted of Madeleine Rydberger, Nils Nostell, Jakob Wijkander and Aleksander Ivarsson.